Skip to content

A retrospective study to evaluate the safety, efficacy and pharmacoeconomics of theophylline sodium glycine sustained-release tablets in the treatment of asthma /COPD

A retrospective study to evaluate the safety, efficacy and pharmacoeconomics of theophylline sodium glycine sustained-release tablets in the treatment of asthma /COPD

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000041086
Enrollment
Unknown
Registered
2020-12-17
Start date
2020-12-16
Completion date
Unknown
Last updated
2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma/ COPD

Interventions

case series:N/A

Sponsors

The Second Affiliated Hospital of Nanhua University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Patients who were diagnosed with asthma/COPD from August 01, 2018 to August 31, 2020 and were hospitalized in the target center; 2) The case records are complete and meet the research conditions; 3) The expected survival period is more than 1 year.

Exclusion criteria

Exclusion criteria: 1) The general conditions, diagnostic information, and medical order record information contained in the observation information are incomplete, or patients whose safety and efficacy judgment are affected by incomplete information; 2) According to the judgment of the investigator, there are other serious accompanying diseases (including but not limited to malignant tumors, severe cardiovascular and cerebrovascular, liver and kidney failure, diabetes, active infections, etc.).

Design outcomes

Primary

MeasureTime frame
Improve breathing restriction;

Countries

China

Contacts

Public ContactTan Xiaowu
573431648@qq.com+86 13974799562

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026